global
outbreak
sever
acut
respiratori
syndrom
sar
caus
novel
coronaviru
sarscov
result
case
fatal
rate
impress
rapid
spread
sarscov
made
great
impact
public
health
socialeconom
stabil
thought
sarscov
might
origin
natur
reservoir
bat
transmit
human
intermedi
palm
civet
raccoon
dog
one
exclud
possibl
recurr
sarscov
envelop
positivestrand
rna
viru
crown
like
spike
protein
two
major
biolog
function
mediat
receptor
angiotensin
convert
enzym
bind
membran
fusion
induc
neutral
antibodi
respons
protein
consid
import
target
develop
diagnost
vaccin
therapeut
receptorbind
domain
rbd
protein
defin
fragment
correspond
residu
protein
mediat
viral
bind
cell
receptor
coincid
identifi
rbd
major
target
neutral
antibodi
propos
ideal
vaccin
antigen
clinic
applic
immunogen
protect
efficaci
rbdbase
vaccin
candid
evalu
anim
model
howev
antigen
immunogen
rbd
human
need
character
detail
toward
develop
rbdbase
vaccin
diagnost
short
commun
found
patient
recov
sar
develop
potent
persist
rbdspecif
antibodi
respons
highlight
potenti
clinic
applic
rbdbase
vaccin
diagnost
two
panel
serum
sampl
recov
sar
patient
use
studi
first
panel
sampl
leftov
previou
studi
collect
convalescentphas
sar
patient
day
onset
ill
outbreak
beij
second
panel
sequenti
sampl
collect
sar
patient
enrol
march
followup
studi
peke
union
medic
colleg
hospit
beij
patient
diagnos
sar
accord
criteria
releas
verifi
serolog
posit
clinic
laboratori
inform
consent
obtain
particip
rbdhi
rbd
sequenc
histag
rbdfc
rbd
fuse
human
iggfc
protein
respect
express
purifi
describ
previous
brief
plasmid
encod
rbdhi
rbdfc
transfect
cell
use
lipofectamin
invitrogen
carlsbad
ca
accord
manufactur
protocol
cultur
medium
replac
fresh
optimem
reducedserum
medium
h
posttransfect
supernat
contain
express
rbd
protein
collect
h
later
rbdhi
purifi
nickel
affin
column
qiagen
rbdfc
purifi
protein
asepharos
fast
flow
amersham
bioscienc
piscataway
nj
reactiv
sar
serum
sampl
purifi
antirbd
antibodi
recombin
rbd
protein
determin
elisa
briefli
purifi
rbdhi
coat
onto
well
microtit
plate
corn
costar
acton
carbon
buffer
ph
overnight
block
nonfat
milk
h
dilut
sampl
ad
incub
h
follow
three
wash
pb
contain
tween
bound
antibodi
detect
hrpconjug
goat
antihuman
igg
invitrogen
carlsbad
ca
h
follow
three
wash
reaction
visual
addit
substrat
tmb
stop
addit
absorb
nm
measur
elisa
micropl
reader
biorad
hercul
ca
total
serum
igg
antibodi
sarscov
measur
use
commerci
avail
whole
viru
lysatesbas
elisa
kit
bjigbi
biotechnolog
beij
china
immunoaffin
resin
purif
rbdspecif
antibodi
prepar
describ
previous
brief
rbdfc
fusion
protein
coupl
cyanogenbromideactiv
sepharos
bead
pharmacia
piscataway
nj
accord
manufactur
instruct
immunoadsorpt
patient
serum
sampl
dilut
pb
incub
rbdfc
resin
overnight
constant
rotat
resin
pack
column
flowthrough
discard
resin
wash
column
volum
pb
bound
antibodi
antirbd
elut
glycinehcl
buffer
ph
eluat
immedi
neutral
tri
buffer
ph
buffer
exchang
pb
sever
cycl
dilut
concentr
amicon
centrifug
filter
devic
millipor
corpor
bedford
purifi
antirbd
antibodi
steril
pore
size
microspin
filter
millipor
concentr
measur
sar
pseudoviru
system
develop
laboratori
previous
describ
brief
cell
cotransfect
plasmid
encod
codonoptim
sarscov
protein
plasmid
encod
envdefect
luciferas
express
genom
use
reagent
invitrogen
accord
manufactur
protocol
supernat
contain
pseudoviru
bear
protein
harvest
h
posttransfect
use
singlecycl
infect
cell
briefli
cell
plate
cellswel
tissu
cultur
plate
grown
overnight
pseudoviru
preincub
serial
dilut
purifi
antirbd
h
addit
cell
cultur
refe
fresh
medium
h
later
incub
addit
h
cell
wash
pb
lyse
use
lysi
reagent
includ
luciferas
kit
promega
madison
wi
aliquot
cell
lysat
transfer
costar
flatbottom
luminomet
plate
corn
costar
corn
ny
follow
addit
luciferas
substrat
promega
rel
light
unit
rlu
determin
immedi
ii
micropl
multimod
reader
turner
biosystem
sunnyval
ca
previou
studi
indic
rbd
protein
major
target
neutral
antibodi
rbdbase
immunogen
could
induc
potent
neutral
respons
protect
immun
anim
model
intend
know
immunogen
rbd
infect
patient
panel
convalesc
sera
collect
sar
patient
day
onset
ill
previous
use
map
antigen
site
sarscov
leftov
sampl
store
expect
maintain
activ
interact
sarscov
antigen
therefor
use
purifi
rbdhi
protein
coat
antigen
elisa
detect
rbdspecif
igg
antibodi
sar
serum
sampl
shown
figur
convalesc
sera
dilut
significantli
react
rbdhi
protein
averag
valu
control
none
sera
healthi
blood
donor
reactiv
antigen
result
demonstr
protein
rbd
highli
immunogen
sarscov
infect
patient
studi
antigen
immunogen
sarscov
human
enrol
cohort
sar
outbreak
patient
followedup
three
year
sequenti
blood
sampl
collect
month
respect
onset
clinic
symptom
serum
sampl
test
dilut
rbdspecif
igg
antibodi
elisa
rbdhi
coat
antigen
parallel
total
serum
igg
antibodi
specif
sarscov
also
detect
use
commerci
elisa
kit
whole
viru
lysat
coat
antigen
serum
sampl
dilut
accord
manufactur
instruct
result
present
figur
rbdspecif
antibodi
maintain
rel
higher
titer
year
followup
year
year
one
sampl
becam
undetect
thu
gave
posit
rate
howev
elisa
result
kit
show
much
low
reactiv
compar
rbdbase
result
od
valu
sampl
drop
dramat
year
special
posit
percentag
year
sampl
suggest
viral
lysatebas
elisa
kit
much
low
sensit
rbdbase
elisa
other
previous
report
rbdspecif
polyclon
monoclon
antibodi
potent
neutral
activ
sarscov
infect
vitro
vivo
kept
ask
whether
rbdspecif
antibodi
respons
serummedi
neutral
activ
end
purifi
rbdspecif
antibodi
immunoaffin
chromatographi
four
sar
serum
sampl
select
convalescentphas
sar
patient
day
onset
ill
beij
outbreak
fusion
protein
rbdfc
coupl
cyanogenbromideactiv
sepharos
bead
serum
sampl
flow
bead
column
absorb
rbdspecif
antibodi
figur
show
purifi
rbdspecif
antibodi
sar
patient
strongli
react
rbdhi
antigen
test
neutral
activ
sar
pseudovirus
consist
four
purifi
human
rbdspecif
antibodi
potent
neutral
infect
sar
pseudovirus
averag
figur
sudden
emerg
sarscov
shock
world
impact
public
health
serious
pandem
contain
high
level
quarantin
disappear
also
rais
numer
mysteri
research
commun
even
today
know
littl
sever
pathogenesi
effect
treatment
protocol
prepared
also
need
effect
diagnost
approach
prevent
vaccin
one
previou
major
find
rbd
protein
serv
main
antigen
site
mediat
neutral
antibodi
respons
clearli
demonstr
rbd
contain
multipl
conformationdepend
neutral
epitop
rbdbase
immunogen
induc
potent
neutral
antibodi
protect
immun
base
observ
propos
rbdbase
sar
vaccin
howev
previou
studi
primarili
base
anim
model
toward
develop
safe
effect
rbdbase
vaccin
one
fundament
question
whether
rbd
immunogen
function
neutral
antibodi
human
ongo
preclin
studi
immunogen
rbd
immunogen
evalu
nonhuman
primat
present
studi
firstli
investig
rbdspecif
antibodi
respons
subject
recov
sarscov
infect
altern
way
evalu
rbd
vaccin
human
recombin
rbd
protein
elisa
antigen
show
spike
rbd
could
induc
potent
persist
antibodi
respons
recov
patient
figur
rbdfc
fusion
protein
immunoaffin
column
antirbd
antibodi
purifi
posit
human
serum
sampl
possess
potent
neutral
activ
figur
therefor
data
verifi
function
sarscov
rbd
infect
subject
highlight
rbdbase
vaccin
human
applic
antibodi
detect
critic
serodiagnosi
sarscov
infect
sensit
specif
current
approach
need
improv
although
number
antigen
includ
protein
peptid
propos
sarscov
serodiagnosi
first
serolog
diagnost
kit
china
base
viral
lysatesderiv
antigen
result
also
demonstr
lysatebas
elisa
kit
show
much
lower
reactiv
human
posit
sera
compar
rbdbase
elisa
figur
surpris
kitbas
result
sinc
similar
serolog
data
previous
report
use
brand
kit
followup
studi
wu
et
al
report
averag
od
valu
drop
year
gave
posit
rate
consist
present
result
therefor
clinic
applic
viral
lysatebas
elisa
kit
might
limit
sensit
specif
develop
novel
improv
approach
sarscov
serodiagnosi
remain
prioriti
protein
rbdbase
method
explor
rbd
specif
mediat
receptorbind
major
antigen
site
anim
human
author
declar
compet
interest
zlc
lfl
lyd
cz
mainli
carri
experi
data
analysi
sbj
tsl
yxh
conceiv
studi
wrote
manuscript
author
read
approv
final
manuscript
